Holen Sie sich die Stockscreener-App
3.345
19.08%
0.54
Schlusskurs vom Vortag:
$2.805
Offen:
$2.74
24-Stunden-Volumen:
4.55M
Relative Volume:
1.61
Marktkapitalisierung:
$257.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-1.0585
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-73.55%
1M Leistung:
-63.81%
6M Leistung:
-75.71%
1J Leistung:
-66.73%
1-Tages-Spanne:
$2.70
$3.85
1-Wochen-Bereich:
$2.68
$13.24
52-Wochen-Spanne:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
3.345 | 955.88M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.68 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.35 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.32 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.60 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.29 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Iovance climbs after FDA rejection for Replimune’s skin cancer drug - MSN
Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha
Fraud Investigation Opened: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) on Behalf of Shareholders - ACCESS Newswire
What analysts say about Replimune Group Inc. stockBreakthrough wealth creation - Autocar Professional
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application - MSN
What drives Replimune Group Inc. stock priceExplosive trading opportunities - Autocar Professional
Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum
Replimune says FDA rejected its lead drug for skin cancer - MSN
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
BMO Capital downgrades Replimune stock to Underperform after CRL - Investing.com Australia
Did You Suffer Losses in Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Replimune Group Surges to 445th in Trading Volume with $255 Million Day Despite 77 Percent Stock Drop - AInvest
Barclays downgrades Replimune Group stock rating to Equalweight on FDA rejection - Investing.com
Replimune CRL Could Hold Warning For Accelerated Approvals - insights.citeline.com
Replimune (REPL) Faces Downgrade and Uncertainty in Latest Analy - GuruFocus
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Business Wire
FDA Rejection Shocks Wall Street, And Craters A Stock - Investor's Business Daily
FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
BMO Capital reiterates Outperform rating on Replimune stock despite FDA setback By Investing.com - Investing.com South Africa
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire
Replimune Group Inc. Stock Analysis and ForecastExceptional market performance - jammulinksnews.com
Market Analysis: July 22nd, 2025 - The Globe and Mail
Leerink Partners downgrades Replimune stock on FDA rejection letter By Investing.com - Investing.com Canada
REPL ALERT: Levi & Korsinsky Investigates Replimune Group, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha
Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
Replimune (REPL) Downgraded to Market Perform by Leerink | REPL Stock News - GuruFocus
Replimune Group Stock Drops Significantly on News of FDA Complete Response LetterKehoe Law Firm, P.C. Investigating Securities Claims on Behalf of InvestorsREPL - ACCESS Newswire
Jefferies lowers Replimune Group stock price target to $6 from $31 - Investing.com India
Replimune drug rejected by FDA; Omega raises $647M biotech fund - BioPharma Dive
Replimune price target lowered to $6 from $31 at Jefferies - TipRanks
Wedbush downgrades Replimune stock to Neutral after FDA rejection By Investing.com - Investing.com South Africa
Barclays maintains Overweight rating on Replimune stock after FDA setback - Investing.com Australia
Replimune Group (REPL) Faces Downgrade with Significant Price Ta - GuruFocus
Replimune Plunges 76.26% Intraday, What Lies Behind the FDA's CRL Rejection? - AInvest
Replimune stock falls after FDA issues CRL for melanoma treatment - Investing.com
Replimune stock falls after FDA issues CRL for melanoma treatment By Investing.com - Investing.com Canada
Wedbush downgrades Replimune stock to Neutral after FDA rejection - Investing.com Australia
JPMorgan downgrades Replimune to Neutral following CRL for cancer drug - TipRanks
BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities - GlobeNewswire
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL - Business Wire
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Replimune Group Plunges 73.3% Intraday, What Now for Replimune's Melanoma Gamble? - AInvest
Replimune rocked by CRL for lead candidate - The Pharma Letter
Mizuho analyst comments on Replimune stock decline following CRL By Investing.com - Investing.com Canada
Replimune (REPL) Group Trading Resumes After Halt | REPL Stock N - GuruFocus
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
4.74%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):